Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
Clinical trial NCT05531526 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05531526
- Sponsor
- AriBio Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-23
- Primary completion
- 2026-05-01
- Enrollment
- 1535
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.